Cancer survival linked to cardiovascular hormone/peptide levels
the ONA take:
Cardiovascular biomarkers such as high circulating levels of cardiovascular hormones/peptides in patients with cancer are linked to shorter survival, according to research published online in Heart.
In this study, researchers sought to determine whether the cancer itself affects levels of cardiovascular hormones/peptides.
The researchers assessed circulating levels of several cardiovascular hormones; proteins indicative of inflammation; and high sensitive troponin (hsTNT), a chemical that regulates heart muscle contractions, in 555 people with a first cancer diagnosis.
None of the participants had yet undergone any drug or radiotherapy treatments that might have damaged their heart tissue. The participants were tracked for an average of 25 months.
Almost one-third of the participants died during the monitoring period. Analysis of their blood samples showed that all the hormones measured and hsTNT increased in tandem with disease severity, sometimes to levels 100 times higher than expected.
The researchers report that their findings suggest that these biomarkers were indicative of heart damage not yet clinically evident, but directly linked to the cancer progression.
Furthermore, the findings suggest that the benefits of heart failure drugs for cancer patients may extend beyond helping to reduce cardiovascular side effects of cancer treatment.
Cardiovascular biomarkers such as high circulating levels of cardiovascular hormones/peptides in cancer are linked to shorter survival.
Sign Up for Free e-newsletters
- Avoiding the ED: Planned Strategies for Unplanned Urgent Cancer Care
- NP-Led Clinics Improved Phase 1 Oncology Study Operations, Outcomes
- Art as Palliative Care: Bedside Intervention Improves Pain, Anxiety, Mood in Hospitalized Cancer Patients
- Unprotected Sex After Chemotherapy
- Mindfulness Training May Improve End-of-Life Conversations in Advanced Cancer
- Study Suggests Greater Focus on the Needs of Family Caregivers of Patients With Cancer
- First Antibody-Based Treatment Regimen Approved for First-Line Treatment of Multiple Myeloma
- Increased Diabetes Risk Associated With Cancer Development
- Childhood Neuroblastoma Survivors at Risk for Psych Impairment
- Drug Classification of Trastuzumab
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|